Post Stem Cell Therapy Testimony of Cerebral Palsy
♫ Wednesday, September 28th, 2011Stem cell therapy done at neurogen brain and spine institute pvt ltd.
See the rest here:
Post Stem Cell Therapy Testimony of Cerebral Palsy
Archive for the ‘Stem Cell Therapy’ Category
What could stem cell therapy do for Peyton?
♫ Monday, September 26th, 2011Indianapolis Colts quarterback Peyton Manning reportedly went to Europe for adult stem cell therapy for his ailing neck, according to published and broadcast reports. But what would such a procedure accomplish, and why would he have to travel to Europe for it?
Read more:
What could stem cell therapy do for Peyton?
Lifeline Skin Care Video: Care For Your Skin with Lifeline Skin Care
♫ Sunday, September 25th, 2011Stem Cell Skin Care
Born Different.
Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.
International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.
Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Lifeline Skin Care Video: Care For Your Skin with Lifeline Skin Care
♫ Sunday, September 25th, 2011Stem Cell Skin Care
Born Different.
Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.
International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.
Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Cancer Stem Cell Chronicle
♫ Sunday, September 18th, 2011About 3 months ago, as an experiment, I launched the Cancer Stem Cell Chronicle, an online daily newspaper that's based on excerpts from 3 streams of content: 1) Twitter content tagged #cancerSC, 2) Twitter content that includes the keywords "cancer stem", and, 3) content derived from a PubMed RSS feed for the search term "cancer stem".
The experiment looks promising. The CSC Chronicle is beginning to provide a convenient way to monitor recent research news about cancer stem cells. Archives are available. The section headings in the CSC Chronicle aren't very meaningful, and should be ignored.
The CSC Chronicle is hosted by Paper.li.
Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss
Cancer Stem Cell Chronicle
♫ Sunday, September 18th, 2011About 3 months ago, as an experiment, I launched the Cancer Stem Cell Chronicle, an online daily newspaper that's based on excerpts from 3 streams of content: 1) Twitter content tagged #cancerSC, 2) Twitter content that includes the keywords "cancer stem", and, 3) content derived from a PubMed RSS feed for the search term "cancer stem".
The experiment looks promising. The CSC Chronicle is beginning to provide a convenient way to monitor recent research news about cancer stem cells. Archives are available. The section headings in the CSC Chronicle aren't very meaningful, and should be ignored.
The CSC Chronicle is hosted by Paper.li.
Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
♫ Friday, September 16th, 2011metromd.net Stem Cell Therapy for Repairing Joint Injuries | Stem Cell Therapy is effective in many orthopedic applications. Restore function and relieve pain from torn ligaments, tendons and damaged cartilage. By Dr
More here:
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
International Stem Cell to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
♫ Sunday, September 11th, 2011
International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.
A webcast of the International Stem Cell Corporation presentation can be viewed live at http://www.wsw.com/webcast/rrshq20/isco. The presentation will be archived and available at the same link for 90 days. After the conference, a link to the presentation will also be posted to the ISCO website, http://www.intlstemcell.com.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Video: The Promising Cells Presented by International Stem Cell Corporation
♫ Sunday, September 11th, 2011Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.
This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).
Executive Producer: Ellis Martin
Producer and Creative Director, Narrator, Editor: Bob Lange
contact: bigskymedia@yahoo.com
Video Link - http://www.youtube.com/watch?v=CcXPMHqENys
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
♫ Sunday, September 11th, 2011
International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.
A webcast of the International Stem Cell Corporation presentation can be viewed live at http://www.wsw.com/webcast/rrshq20/isco. The presentation will be archived and available at the same link for 90 days. After the conference, a link to the presentation will also be posted to the ISCO website, http://www.intlstemcell.com.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Video: The Promising Cells Presented by International Stem Cell Corporation
♫ Sunday, September 11th, 2011Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.
This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).
Executive Producer: Ellis Martin
Producer and Creative Director, Narrator, Editor: Bob Lange
contact: bigskymedia@yahoo.com
Video Link - http://www.youtube.com/watch?v=CcXPMHqENys
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Duffy Update, Post Stem Cell Therapy
♫ Monday, September 5th, 2011Aarff.com does a followup on Duffy, a 10 year old Lab who underwent stem cell therapy two months ago in June 2011
Go here to see the original:
Duffy Update, Post Stem Cell Therapy
Spinal Cord Injury – Stem Cell Therapy
♫ Saturday, September 3rd, 2011Franklin is a patient with spinal cord injury.
Continued here:
Spinal Cord Injury - Stem Cell Therapy
International Stem Cell Corporation presents "The Promising Cells" Video
♫ Sunday, August 28th, 2011In this video presentation, see and hear an overview of International Stem Cell Corporation (ISCO.OB). ISCO has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy. You'll hear directly from Executive Chairman, Kenneth Aldrich. Lifeline Cell Technology and Skin Care Products, revenue generating units of ISCO are also reviewed.
This presentation was produced by Big Sky Productions, INC (BGSI.OB), Co-Executive Producers Ellis Martin and Bob Lange.
contact: bigskymedia@yahoo.com
Unfortunately, this content is currently being updated and will be posted again soon.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Onemedplace.com Interview – "International Stem Cell Corp Develops Similar Embryonic Stem Cells Without Fertilized Embryos"
♫ Sunday, August 28th, 2011
Ken Aldrich, Executive Chairman of International Stem Cell Corporation [OTC:ISCO] was interviewed by OneMedRadio where he discussed the company’s regenerative medicine therapies.
Brett Johnson: Good day, this is Brett Johnson in New York City with OneMedRadio. Today, I am with Ken Aldrich. He is the co-founder and executive chairman for International Stem Cell, symbol ISCO on the bulletin board. It is a Carlsbad, California company in the stem cell business. Ken, thanks for joining us today.
Kenneth Aldrich: Thank you. I appreciate the opportunity to speak with you.
BJ: Ken, go ahead and tell us a little bit about the business of International Stem Cell and what you guys are doing that’s unique and distinctive.
KA: I’d be happy to. International Stem Cell is in the regenerative medicine business broadly speaking. We produce and develop therapies that are based on what are called pluripotent stem cells. Pluripotent stem cell simply means a stem cell that can be converted (the technical word is differentiated) into any cell in the body and theoretically treat any kind of disease that can be treated with cell therapy.
There are today basically only two ways to create a pluripotent stem cell. One is what’s been around for ten years called embryonic stem cells derived from a fertilized human embryo, and the other is parthenogenesis, which is our own creation, our own patent. Our people really developed it from the very beginning.
They function very much the same but we have two unique advantages. One, we take the ethical issue right off the table. We do not use a fertilized egg and we never damage or destroy anything that could become a human being. And second, the DNA that results when we go through that process of using only an unfertilized egg is a much simpler DNA structure. It’s complete, but simpler in its form. It enables us to use a single cell line from a single donor to match very large numbers of people. So it gives us the potential a few years down the road to have a true stem cell bank. And by that I don’t mean the banking of somebody’s own cells, but a bank much like a blood bank in which any patient who needs stem cells can come, get cells that will match their immune system and thereby eliminate or reduce the need for immunosuppressant drugs.
We think ultimately that’s going to be the single defining differentiator for our company because a cell transplant is like a miniature organ transplant. If the body rejects it, there’s no benefit, and we’re working on a way to provide cells that anyone can use at any time for any disease that any scientist is smart enough to figure out a way to treat with cells. It’s a tall order but we think we’re up to it.
To read the full text or listen to the interview, please visit onemedplace -http://www.onemedplace.com/blog/archives/9031
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th
♫ Sunday, August 28th, 2011International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.
The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at http://www.CaliforniaStocks.com
A webcast of the International Stem Cell Corporation presentation will be accessible online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at http://www.internationalstemcell.com. An archived version will be available for 30 days.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Corporation presents “The Promising Cells” Video
♫ Sunday, August 28th, 2011In this video presentation, see and hear an overview of International Stem Cell Corporation (ISCO.OB). ISCO has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy. You'll hear directly from Executive Chairman, Kenneth Aldrich. Lifeline Cell Technology and Skin Care Products, revenue generating units of ISCO are also reviewed.
This presentation was produced by Big Sky Productions, INC (BGSI.OB), Co-Executive Producers Ellis Martin and Bob Lange.
contact: bigskymedia@yahoo.com
Unfortunately, this content is currently being updated and will be posted again soon.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Onemedplace.com Interview – “International Stem Cell Corp Develops Similar Embryonic Stem Cells Without Fertilized Embryos”
♫ Sunday, August 28th, 2011
Ken Aldrich, Executive Chairman of International Stem Cell Corporation [OTC:ISCO] was interviewed by OneMedRadio where he discussed the company’s regenerative medicine therapies.
Brett Johnson: Good day, this is Brett Johnson in New York City with OneMedRadio. Today, I am with Ken Aldrich. He is the co-founder and executive chairman for International Stem Cell, symbol ISCO on the bulletin board. It is a Carlsbad, California company in the stem cell business. Ken, thanks for joining us today.
Kenneth Aldrich: Thank you. I appreciate the opportunity to speak with you.
BJ: Ken, go ahead and tell us a little bit about the business of International Stem Cell and what you guys are doing that’s unique and distinctive.
KA: I’d be happy to. International Stem Cell is in the regenerative medicine business broadly speaking. We produce and develop therapies that are based on what are called pluripotent stem cells. Pluripotent stem cell simply means a stem cell that can be converted (the technical word is differentiated) into any cell in the body and theoretically treat any kind of disease that can be treated with cell therapy.
There are today basically only two ways to create a pluripotent stem cell. One is what’s been around for ten years called embryonic stem cells derived from a fertilized human embryo, and the other is parthenogenesis, which is our own creation, our own patent. Our people really developed it from the very beginning.
They function very much the same but we have two unique advantages. One, we take the ethical issue right off the table. We do not use a fertilized egg and we never damage or destroy anything that could become a human being. And second, the DNA that results when we go through that process of using only an unfertilized egg is a much simpler DNA structure. It’s complete, but simpler in its form. It enables us to use a single cell line from a single donor to match very large numbers of people. So it gives us the potential a few years down the road to have a true stem cell bank. And by that I don’t mean the banking of somebody’s own cells, but a bank much like a blood bank in which any patient who needs stem cells can come, get cells that will match their immune system and thereby eliminate or reduce the need for immunosuppressant drugs.
We think ultimately that’s going to be the single defining differentiator for our company because a cell transplant is like a miniature organ transplant. If the body rejects it, there’s no benefit, and we’re working on a way to provide cells that anyone can use at any time for any disease that any scientist is smart enough to figure out a way to treat with cells. It’s a tall order but we think we’re up to it.
To read the full text or listen to the interview, please visit onemedplace -http://www.onemedplace.com/blog/archives/9031
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th
♫ Sunday, August 28th, 2011International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.
The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at http://www.CaliforniaStocks.com
A webcast of the International Stem Cell Corporation presentation will be accessible online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at http://www.internationalstemcell.com. An archived version will be available for 30 days.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Stem Cell Therapy – Treatment for Severe Hip Pain
♫ Friday, August 26th, 2011Cathy received stem cell and adipose derived stem cell injections to help her with severe hip problem. She has been in severe pain for 8 months until Dr.
See the original post here:
Stem Cell Therapy - Treatment for Severe Hip Pain